Compelling or irrelevant? Using number needed to treat can help decide.
about
Psychosocial interventions for retention in drug abuse treatmentAcamprosate for alcohol dependenceOpioid antagonists for alcohol dependencePsychosocial interventions for retention in drug abuse treatmentManagement of antipsychotic-related weight gainLurasidone for the treatment of bipolar depression: an evidence-based reviewPhosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsHow to obtain NNT from Cohen's d: comparison of two methodsA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability.Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderNumber needed to treat analyses of drugs used for maintenance treatment of bipolar disorder.A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents.Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysisTreatment implications of predominant polarity and the polarity index: a comprehensive review.Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.Quantifying clinical relevance in the treatment of schizophrenia.Schizophrenia, obesity, and antipsychotic medications: what can we do?Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?Patterns of therapeutic alliance: rupture-repair episodes in prolonged exposure for posttraumatic stress disorder.Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.Olanzapine-fluoxetine combination for the treatment of bipolar depression.Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Comparison of different adjuvant therapies for 9 resectable cancer types.Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Treatment of bipolar depression: making sensible decisions.Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature.A primer on binge eating disorder diagnosis and management.Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
P2860
Q24186889-7CA69046-0D98-4822-81AD-1879624CB286Q24235594-0C5961DB-919D-4709-A34B-D7C314D4005AQ24235797-590DBAB0-DB92-4232-97B2-205BC3E0F7D4Q24239860-2D7C59E7-67CA-4F49-9717-FA0AA1860C92Q24610124-42D4D25E-AB9F-4407-AF7E-8B46BC4FC45DQ26796437-69DCF1A3-9668-4B76-B27F-11D49F433D5AQ26800403-B5AC6454-CDF0-4D28-B25E-CFBD195D4D16Q28740693-03D7594B-29D1-41C5-9F9C-4381E88AF6B3Q30353864-9A1ABC79-24AF-491E-8475-D51D7CA284DBQ30370326-8F559669-05D0-4FA3-A4E6-641F9196A49BQ33899006-F5DCE10C-8CA3-4B30-8FBB-40F09CB57747Q33964496-C9522124-D5C5-4F9B-B1E4-E52D3DAA200DQ34010693-B15DCA82-FFFD-4E50-A8DF-243BEB72C86AQ34148283-B43AAB1F-B65F-46AD-9BD4-4B8A72B8DA51Q34252774-1431BEB0-011C-4F19-B61D-3F2D5874E1F2Q34347796-428E2715-9966-4C6F-B1AB-505D7130F274Q34369664-12A9DE9D-87C1-4CDB-BCDA-141D98AB0AE5Q34501911-5C9C92D5-71A9-4C72-A657-DBCC06E0EEDDQ34626111-4577D099-4C5B-417B-B451-A05835DFF9BBQ34634926-057D8DD9-7DCC-4815-B5D2-2DEEB315ABB6Q34661011-3F585C47-E848-4048-9F0D-A5716EBDCA26Q35203680-26D29155-23D5-4A7A-8511-1A3ABB3CC575Q35544274-D42A0260-E809-42BD-92B1-12CF16E5AE8DQ35819467-C13DBC55-5ED6-46E8-8448-260A456C2670Q37226376-1801714F-E1ED-4EB7-9AD7-32544ABADFF7Q37356492-743FDC62-8F3A-4DD8-B90C-F5F814841E73Q37579009-5FB8CC08-7B37-47A9-91FF-E4564FABA3A1Q37777006-AAF841A4-3FA2-4BF9-9897-94627371CAE9Q37815561-86A3DC1A-8814-49CD-AEC7-8AA8FDAE1EFEQ37950471-5CC0CAED-CA61-4B5D-BF94-0A1BBC0B2CBDQ37979497-9CEE41D5-D5FE-467F-BB85-A8F9D1E905BEQ38097886-DF5BA949-973B-4A61-B808-FE9F21DCB04BQ38118480-B84395E3-A484-45D8-BD3F-E44BDB3D1978Q38156001-3FE04B07-65D6-4863-9B2D-6D8D0E06218CQ38250849-924039D4-EFAE-4414-B54B-21140824D98EQ38269372-AD4FE2F3-340F-4DCA-81F5-76C44615EBDDQ38370764-45BCB060-C335-4C87-87FA-65E088A2BEEBQ38563874-CC6AF633-930D-4DFF-8118-26F8412B8962Q38673549-3244F5AD-C29D-4792-8FB4-C3F1AF3F79ACQ38789841-3E1ED2B8-2ED1-475A-8D83-2183EC4029F0
P2860
Compelling or irrelevant? Using number needed to treat can help decide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Compelling or irrelevant? Using number needed to treat can help decide.
@en
Compelling or irrelevant? Using number needed to treat can help decide.
@nl
type
label
Compelling or irrelevant? Using number needed to treat can help decide.
@en
Compelling or irrelevant? Using number needed to treat can help decide.
@nl
prefLabel
Compelling or irrelevant? Using number needed to treat can help decide.
@en
Compelling or irrelevant? Using number needed to treat can help decide.
@nl
P2860
P1476
Compelling or irrelevant? Using number needed to treat can help decide.
@en
P2860
P304
P356
10.1111/J.1600-0447.2008.01194.X
P407
P577
2008-06-01T00:00:00Z